🇺🇸 hetrombopag in United States

29 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Myelosuppression — 9 reports (31.03%)
  2. Off Label Use — 3 reports (10.34%)
  3. White Blood Cell Count Decreased — 3 reports (10.34%)
  4. Acute Kidney Injury — 2 reports (6.9%)
  5. Cardiac Arrest — 2 reports (6.9%)
  6. Coma — 2 reports (6.9%)
  7. Disseminated Intravascular Coagulation — 2 reports (6.9%)
  8. Disseminated Varicella Zoster Virus Infection — 2 reports (6.9%)
  9. Drug Ineffective — 2 reports (6.9%)
  10. Hepatic Failure — 2 reports (6.9%)

Source database →

hetrombopag in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is hetrombopag approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for hetrombopag in United States?

Sun Yat-sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.